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Abstract
Background
The Zika virus (ZIKV) has been associated with Guillain-Barre´ syndrome (GBS) in epidemio-
logical studies. Whether ZIKV-associated GBS is related to a specific clinical or electrophys-
iological phenotype has not been established. To this end, we performed a systematic
review and meta-analysis of all published studies on ZIKV-related GBS.
Methods
We searched Pubmed, EMBASE and LILACS, and included all papers, reports or bulletins
with full text in English, Spanish or Portuguese, reporting original data of patients with GBS
and a suspected, probable or confirmed recent ZIKV infection. Data were extracted accord-
ing to a predefined protocol, and pooled proportions were calculated.
Results
Thirty-five studies were included (13 single case reports and 22 case series, case-control or
cohort studies), reporting on a total of 601 GBS patients with a suspected, probable or con-
firmed ZIKV infection. Data from 21 studies and 587 cases were available to be summa-
rized. ZIKV infection was confirmed in 21%, probable in 22% and suspected in 57% of
cases. ZIKV PCR was positive in 30% (95%CI 15–47) of tested patients. The most common
clinical features were: limb weakness 97% (95%CI 93–99), diminished/absent reflexes 96%
(95%CI 88–100), sensory symptoms 82% (95%CI 76–88), and facial palsy 51% (95%CI
44–58). Median time between infectious and neurological symptoms was 5–12 days. Most
PLOS NEGLECTED TROPICAL DISEASES
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008264 April 27, 2020 1 / 24
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Leonhard SE, Bresani-Salvi CC, Lyra
Batista JD, Cunha S, Jacobs BC, Brito Ferreira ML,
et al. (2020) Guillain-Barre´ syndrome related to
Zika virus infection: A systematic review and meta-
analysis of the clinical and electrophysiological
phenotype. PLoS Negl Trop Dis 14(4): e0008264.
https://doi.org/10.1371/journal.pntd.0008264
Editor: Elvina Viennet, Australian Red Cross
Lifelood, AUSTRALIA
Received: January 9, 2020
Accepted: March 31, 2020
Published: April 27, 2020
Copyright: © 2020 Leonhard et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: SEL, CCBS, MLBF, MFPMA and BCJ are
supported by ZikaPLAN, a global research
consortium funded by the European Union within
the Horizon2020 program (grant agreement
number: 734584). The funding body had no role in
the design, acquisition or interpretation of the data.
cases had a demyelinating electrophysiological subtype and half of cases were admitted to
the Intensive Care Unit (ICU). Heterogeneity between studies was moderate to substantial
for most variables.
Conclusions
The clinical phenotype of GBS associated with ZIKV infection reported in literature is gener-
ally a sensorimotor demyelinating GBS with frequent facial palsy and a severe disease
course often necessitating ICU admittance. Time between infectious and neurological
symptoms and negative PCR in most cases suggests a post-infectious disease mechanism.
Heterogeneity between studies was considerable and results may be subject to reporting
bias. This study was registered on the international Prospective Register of Systematic
Reviews (CRD42018081959).
Author summary
Guillain-Barre´ syndrome (GBS) is a rare but severe neurological disease, characterized by
an acute onset flaccid paralysis. GBS is thought to be caused by an exaggerated immune
response to common infections that damages the peripheral nerves. The Zika virus
(ZIKV) is the most recent pathogen to be connected to GBS, when large outbreaks of
ZIKV infection in French Polynesia and Latin America were followed by an increased
incidence of GBS patients. To better understand the clinical features and outcome of
ZIKV-related GBS, we have performed a systematic review and meta-analysis of all pub-
lished studies on GBS related to ZIKV. We identified 35 studies, reporting on a total of
601 patients with GBS and a suspected, probable or confirmed Zika virus infection, and
were able to summarize data of 587 patients from 21 studies in a pooled analysis. Our
study shows that published cases with ZIKV-related GBS generally have both sensory and
motor symptoms, facial palsy, demyelination on electrophysiological examination, and a
severe disease course that often necessitates ICU admittance. The relatively long time
between infectious and neurologic symptoms and the lack of detection of viral particles in
bodily fluids in most patients suggest a post-infectious rather than an infectious pathogen-
esis. However, these results should be interpreted taking into account the heterogeneity
between studies, which was considerable for many variables, and a possible reporting bias
of more severe cases. Outbreaks of ZIKV and GBS may appear in the future and our study
can help clinicians in diagnosing and managing GBS patients in ZIKV endemic areas, and
increases our understanding of the neuropathology of ZIKV.
Introduction
Guillain-Barre´ syndrome (GBS) is the most common cause of acute flaccid paralysis world-
wide, with an incidence rate of approximately 1 per 100,000 person-years.[1] GBS is an acute
immune-mediated polyradiculoneuropathy, and is presumed to be triggered by preceding
infections with specific pathogens, such as Campylobacter jejuni, cytomegalovirus (CMV), and
Epstein-Barr virus (EBV).[2] Recently, the incidence of GBS increased during Zika virus
(ZIKV) epidemics in French Polynesia (2013) and Latin America (2015–2016) and an associa-
tion between GBS and ZIKV was established through epidemiological studies.[3, 4]
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The classic form of GBS is characterized by a rapidly progressive and symmetrical weakness
of the limbs, with sensory symptoms and reduced or absent tendon reflexes.[4] Cranial nerve
involvement is frequent, with facial and bulbar muscles most often affected.[5] Electrophysio-
logical studies help to confirm the diagnosis of GBS, and can indicate different subtypes,
including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor
axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN).[4]
The majority of patients will lose the ability to walk during the acute phase of the disease and
about 25% of patients need to be mechanically ventilated at the Intensive Care Unit (ICU).[6]
Clinical presentation and severity of GBS can vary extensively between patients. This variabil-
ity is thought to be, in part, caused by differences in the type of preceding infections. For
instance, C. jejuni has been associated with a pure motor axonal form of GBS with a severe dis-
ease course, while CMV has been linked to a sensorimotor GBS with pronounced respiratory
insufficiency.[6–8]
Since the ZIKV epidemics, numerous studies have been published on ZIKV-related GBS,
but it has not been established if there is a specific clinical and electrophysiological phenotype
of GBS after ZIKV, and whether this differs from GBS triggered by other pathogens.[3, 4]
Therefore, we have performed a systematic review and meta-analysis of all published studies
on ZIKV-related GBS, and give a comprehensive overview of demographic characteristics,
clinical features, diagnostic investigations, and outcome of ZIKV-related GBS patients.
Methods
This systematic literature review follows the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement and was registered on the international Prospective
Register of Systematic Reviews (PROSPERO) with number CRD42018081959.[9]
Information sources and search strategy
First, by selecting key words from relevant articles, search strategies were constructed for the
Pubmed, EMBASE and LILACS databases (Fig 1), which were searched on 24 November 2017
and on 24 January 2019. Second, the titles and abstracts were screened by two researchers
(JDLB and SC) to identify the key words (‘Guillain-Barre Syndrome’, ‘viruses’, ‘virus’, ‘Zika
virus’ and ‘Zika’), and to exclude in vitro or in animal studies and reports from meetings or
congresses. The selected papers were read in full by two independent reviewers (CCBS,
MFPMA) and a third reviewer (SEL) was consulted in case of disagreement.
We included all papers, reports or bulletins with available full text in English, Spanish or
Portuguese, without restriction in year of publication, reporting original data of patients with
GBS and a suspected, probable or confirmed recent ZIKV infection, of any age, gender and in
any setting. Predefined exclusion criteria were: GBS within 3 months after a vaccination or
other proven triggering infection (e.g. C. jejuni), and studies with no information on age, resi-
dence, and at least one clinical variable of interest. When the study population of reported
cases overlapped with cases published in other papers, the paper reporting the highest amount
of cases was included. When only part of the cases in a study fulfilled our inclusion criteria,
only these cases were included, but if separate data of these cases were not available after con-
tacting the corresponding author, the article was excluded.
Data extraction and management
Data were extracted independently by one of three reviewers (CCBS, MFPMA, SEL) according
to a predefined protocol. The data extraction was then checked by one of the other two review-
ers, and discrepancies were solved by discussion among all of them. Variables of interest
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comprised demographics, clinical characteristics (symptoms and signs of arbovirus infection
and GBS), ancillary diagnostic investigations (electrophysiology and CSF), treatment, clinical
course, and outcome of GBS. The corresponding authors were requested to share data on vari-
ables of interest that were not reported.
Cases were classified according to the reported diagnostic certainty levels for GBS and
ZIKV infection. To classify the diagnosis GBS we employed the Brighton Collaboration
Fig 1. PRISMA Flowchart of search and selection of studies on GBS associated with recent ZIKV infection. �excluding Geurtsvankessel et al. (only one GBS case
associated with a recent ZIKV infection).
https://doi.org/10.1371/journal.pntd.0008264.g001
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Criteria (2011).[10] If the Brighton Criteria were not reported, these were defined based on
available reported data, and if the clinical description did not correspond to the reported
Brighton level, cases were reclassified after clarification was sought with the corresponding
author. The diagnostic certainty of ZIKV infection was classified as confirmed, probable or
suspected, according to the Centers for Disease Control and Prevention (CDC) criteria[11]
(Table 1), based on the results of laboratory tests: case-by-case in case reports and series, and
all cases combined in larger studies.
Clinical characteristics were retrieved as the number of patients in whom the variable was
present in the numerator, and the total number of reported cases in the denominator: n/N
(%). For arbovirus symptoms, we assumed symptoms were absent rather than missing if they
were not cited in the manuscript, to account for the reporting bias, and therefore described as
zero (n) out of the total number of reported cases (N). For the neurologic findings, variables
not cited were considered missing data, because a risk of measurement bias was deemed higher
than a risk of a reporting bias for these variables. If clinical characteristics were reported at
multiple time points, data representing the full disease course were presented. Continuous var-
iables (age, time between infectious and neurologic symptoms, duration of progression and
plateau phase of GBS, duration hospital admission) were extracted as medians and or means,
depending on how they were presented in the original article.
Statistical analysis
First, we calculated the proportions per study of each variable of interest, and then the pooled
proportions with data from all included studies reporting more than one GBS case. We were
unable to summarize continuous variables, as in most studies these were reported as medians
without availability of individual data or means. To address the possibility of an ascertainment
bias of ZIKV infection among study populations, we then performed a subgroup sensitivity
analysis, repeating the pooled analysis with grouped data of only probable or confirmed ZIKV
cases (overall study populations comprising only probable/confirmed ZIKV cases, and sub-
samples of probable/confirmed cases from studies that also included suspected ZIKV cases,
when available). We also performed sensitivity analyses by excluding papers that recruited
only ICU patients, to account for selection bias in the pooled proportion of mechanical ventila-
tion and ICU assistance.
Table 1. Zika virus disease case definition.
Suspected Acute onset of fever (measured or reported), OR maculopapular rash, OR arthralgia, OR conjunctivitis;
OR Guillain-Barre´ syndrome (not explained by another etiology)�
Probable Suspected ZIKV disease AND
Epidemiologic linkage AND
Laboratory evidence of recent ZIKV or flavivirus infection by:
• Positive ZIKV IgM (serum/CSF) with:
˚ Positive neutralizing antibody titers against ZIKV and DENV (or other flaviviruses endemic to region
of exposure) OR
˚ Negative DENV IgM and no neutralizing antibody testing performed.
Confirmed Suspected ZIKV disease AND
Laboratory evidence of recent ZIKV infection by:
• Positive ZIKV culture, viral antigen or RNA (serum, CSF, tissue, or other specimen) OR
• Positive ZIKV IgM (serum/CSF) with positive ZIKV and negative DENV (or other flaviviruses
endemic to region of exposure) neutralizing antibody titers
Zika virus case definition according to the Centers for Disease Control (CDC).[11] ZIKV = Zika virus |
DENV = Dengue virus | CSF = cerebrospinal fluid | RNA = Ribonucleic acid
�During a ZIKV epidemic
https://doi.org/10.1371/journal.pntd.0008264.t001
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The pooled proportions and the 95% confidence intervals (CI) were estimated using the
random effects model and the Freedman Tukey double arcsine transformation, to account for
proportions near 0 and 1. Heterogeneity between studies was calculated using the Chi-square
test and I2 statistics, which was interpreted as follows: not important (I2 = 0–40%); moderate
(I2 = 30–60%); substantial (I2 = 50–90%); considerable (I2 = 75–100%).[12] The meta-analysis
was done using the metaprop command in STATA 15.1.[13]
Results
Study selection
We identified 1716 articles in the databases researched, of which 35 studies were included in
our systematic review. The 35 selected studies reported on a total of 601 GBS cases with a sus-
pected, probable or confirmed ZIKV infection with data of at least one variable of interest, and
consisted of 13 single case reports and one cohort in which only one case fulfilled our inclusion
criteria (n = 14, Table 2), and 14 case series and seven case-control studies (n = 587, Table 3).
For the pooled analysis of the studies, we were only able to use the studies that reported on
more than one case. (Table 3). For the subgroup meta-analysis of probable/confirmed ZIKV
cases, data of 165 GBS cases with probable or confirmed ZIKV infection, from 14 studies,
could be pooled (Fig 1).
Study characteristics: case selection, case ascertainment and risk of bias
In Table 2, the single case reports are presented alphabetically with a brief clinical description
per case. Eleven cases were from ZIKV epidemic or endemic regions and three were travelers
returning from epidemic regions. Eight cases were positive for ZIKV PCR, four for IgM and
plaque-reduction neutralization test (PRNT), and two were reported to be ZIKV positive with
no further information provided. Six of eight cases of whom the Brighton classification was
reported, fulfilled level 1. The most frequent clinical phenotype was a demyelinating sensori-
motor GBS with facial and/or bulbar palsy.
In Table 3, the 21 studies reporting more than one patient are displayed according to the
location and time-period of cases, in line with the global spread of the ZIKV epidemics on the
Pacific islands (Oct 2013-Dec 2014) and Latin America (Dec 2014–2017). The first study was
from French Polynesia in 2013–2014,[4] and the last was from Mexico in 2016–2017.[14] One
study reported cases during and outside of a ZIKV outbreak period in Singapore[15]
Inclusion criteria, case selection and setting differed between studies. A diagnosis of GBS
was the inclusion criterion in 14 studies, and seven studies also included other acute neuro-
logic illnesses besides GBS.[16–22] Six studies included all GBS patients in their reference pop-
ulation,[4, 15, 23–26] one study included all GBS patients >12 years old,[27] and one study
included all arbovirus-related neurologic manifestations.[19] All other studies included a con-
venience sample of patients seen at one or more health-care centres. Three studies only
included patients admitted to the ICU,[17, 22, 28] and nine studies only included GBS patients
with a clinical suspicion or laboratory evidence of a ZIKV infection.[14, 17, 20–22, 28–31]
Seven studies were set in a specialized hospital (academic or reference centre),[4, 16, 18, 23, 26,
31, 32] and two multi-centre studies were set in both specialized and non-specialized hospitals.
[21, 28] These differences are potential sources of selection bias within studies and heterogene-
ity across studies.
Sixteen studies reported the criteria that were applied for diagnostic certainty of GBS, and
13 used the Brighton Criteria. In four studies the Brighton Criteria were prospectively applied
by a physician; in seven, retrospectively through records review; two studies gave no informa-
tion on how the Brighton level was assessed; and three employed other criteria. The risk of
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Table 2. Single case reports of Guillain-Barre´ syndrome with recent ZIKV infection.
First author Journal, year City, country Period Clinical description ZIKV diagnosis
Beattie[34] Infect Dis Clin
Pract
2018
Dominican
Republic (DR)
2016 64 y/o woman returning from DR to USA. Paresthesias,
sensory signs, tetraparesis, areflexia, difficulty walking,
facial palsy. Preceding (10d) fever, rash, malaise,
arthralgia, conjunctivitis, headache, cough, rhinorrhea.
CSF: ACD. EMG: AIDP with axonal damage. Brighton
level 1.
Treatment: IVIg. ICU and MV. Discharge at 35d
(tetraparesis).
ZIKV PCR+ (S,U)
IgM: ZIKV- (S,CSF), DENV/
CHIKV- (S)
VNT ZIKV< DENV (S)
Brasil[35] Lancet
2016
Rio de Janeiro,
Brazil
Jun 2014 24 y/o woman. Paresthesias, tetraparesis, areflexia,
difficulty walking. Concurrent fever, rash, headache,
ocular pain, conjunctivitis, edema. Normal CSF and EMG.
Brighton level 3.
No treatment. Discharge at 13d (recovered).
PCR: ZIKV+ (S,CSF,U,Sa)
PCR: DENV/CHIKV-(S, CSF)
Fabrizius[36] Am J Trop Med
Hyg
2016
Guyana Mar 2016 44 y/o man. Paresthesias, sensory signs, ataxia, LL paresis,
areflexia. Preceding (8d) fever, headache, rash, arthralgia,
arthritis, conjunctivitis. CSF: ACD. EMG: sensorimotor
peripheral neuropathy. Brighton 1.
Treatment: IVIg. Discharge at 15d (walking with aid).
PCR: ZIKV/DENV/CHIKV-
(S), ZIKV+ (U)
IgM: ZIKV+ (S,CSF); DENV/
CHIKV- (S)
VNT ZIKV = DENV
Fontes[37] Neuroradiol
2016
Rio de Janeiro,
Brazil
2016 51 y/o woman. LL paresis, difficulty walking, facial palsy.
Preceding (?d) rash, myalgia, arthralgia, conjunctivitis.
CSF: ACD. EMG: AIDP.
Treatment: IVIg. Clinical improvement. Discharge NR.
ZIKV+ (S,U–type tests NR)
Gonzalez-Escobar
[38]
Rev Panam
Salud Publica
2016
Tunapuna,
Trinidad
Tobago
Aug 2016 29 y/o man. Paresthesias, ataxia, LL paresis and
progressing to tetraparesis. Preceding (7d) fever, rash,
headache, malaise.
Treatment: IVIg. Mild weakness at 10m.
PCR: ZIKV+(S), DENV/
CHIKV-(S)
IgM: ZIKV/DENV/CHIKV-
(S)
Geurtsvankessela[39] Ann Clin Transl
Neur, 2018
Dhaka,
Bangladesh
Nov
2013-Dec
2015
58 y/o woman. Distal hypesthesia, tetraparesis, facial and
bulbar palsy, autonomic symptoms (constipation).
Treatment: IVIg. Independent walking at 3m.
IgM, IgG, VNT: ZIKV+ (S)
PCR: ZIKV- (S)
Hamer[40]b Ann Intern Med
2017
Suriname May
2015-Feb
2016
60 y/o woman Returning from Surinam to the
Netherlands. Tetraparesis, bulbar and bilateral facial palsy,
areflexia, sensory signs. Preceding (?d) fever, myalgia,
diarrhea, vomiting. CSF: ACD. EMG: AIDP. Brighton 1.
Hospitalized 15d.
PCR: ZIKV+(U, S)
IgM: ZIKV+(CSF).
Kassavetis[41] Neurology
2016
Haiti Jan 2016 35 y/o man. Paresthesias, sensory signs, bulbar and
bilateral facial palsy, ophthalmoplegia, ataxia, areflexia.
Preceding (1d) fever, headache, ocular pain, nasal
congestion. CSF: ACD. Brighton 2 (MFS-GBS overlap).
Treatment: IVIg. Discharge at 5d, walking with aid at 3w.
IgM&VNT: ZIKV+(S,CSF)
Miller[42] J Neurol Sci
2017
Dominican
Republic
May 2016 55 y/o woman. Paresthesias, LL paresis progressing to
tetraparesis, bulbar and sensory signs, ataxia, areflexia.
Concurrent asthenia, malaise, myalgia. CSF: ACD. EMG:
AIDP. Brighton 1.
Treatment: IVIg. Discharge at 22d (walking with aid).
PCR: ZIKV-(S,CSF,U)
IgM: ZIKV+ (S,CSF), DENV
+(S),CHIKV-(S)
VNT ZIKV< DENV (S)
Rabelo[43] Front Microbiol
2018
Rio de Janeiro,
Brazil
Jun 2016 28 y/o pregnant woman (stillbirth). LL paresis
progressing to tetraparesis, unable to walk, areflexia,
paresthesias, sensory, autonomic, and respiratory signs.
Preceding (20d) rash, vomiting. CSF: normal. EMG:
AMSAN. Treatment: IVIg. Discharge at 28d, walking with
aid at 40d.
ZIKV confirmed in placental
and fetal tissues
IgM: ZIKV/DENV/CHIKV-
(S)
Raboni[44] Transpl Infect
Dis
2017
Maranhão,
Brazil
Jun 2015 9 y/o girl. LL paresthesia, paresis, unable to walk,
progressing to respiratory dysfunction. Preceding (90d)
hematopoietic stem cell transplant. CSF: raised cell count
and protein level. EMG: AIDP.
Treatment: IVIg and PE. ICU, MV. Hospitalized (?d).
Recovered at 4m.
PCR: ZIKV/DENV-(S), DENV
NS1-
IgM: ZIKV/DENV+(S)
VNT ZIKV< DENV
(Continued)
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ascertainment bias of GBS is likely to be low or very low, as the vast majority of all cases with
this data available in this review fulfilled Brighton levels 1–3 (396/407, 97%).
Regarding the ascertainment of ZIKV infection, 13 studies tested their cases for both PCR
and IgM,[4, 14–18, 21, 25, 26, 28, 30, 31, 33] five only for PCR,[19, 20, 22, 29, 32] and three
only for IgM.[23, 24, 27] Based on the CDC ZIKV case definition, more than a half of all GBS
cases with this data available had a suspected ZIKV infection (324/570, 57%), which gives a
high risk for ascertainment bias within studies and heterogeneity across studies.
Patient characteristics
Demographics. The median age of the study populations varied between 34 and 61 years,
and only 11 pediatric patients were included in four studies.[19, 24, 27, 30] The majority of
patients was male (62%) and the male:female ratio of all studies combined was 1.63. In multi-
center studies or those including all GBS cases in the reference population, the male:female
ratio was 1:1, with the exception of studies from French Polynesia[4] and Martinique[26],
which had ratios of 3:1 and 2:1, respectively (Table 3).
Certainty levels of GBS diagnosis and ZIKV infection. Separate proportions of each
Brighton level (1–4) were available in ten studies[14, 16–18, 20, 27, 31–33] (295 cases): 110
cases fulfilling level 1; 146 level 2; 26 level 3 and 13 level 4. Miller Fisher Syndrome (MFS) was
reported in only four studies: one study from Singapore (five cases),[15] and three studies
from Latin America (six cases).[14, 18, 32] ZIKV infection was confirmed in 118 (21%), proba-
ble in 128 (22%) and suspected in 324 (57%) of all cases with reported separate proportions of
each ZIKV certainty level. In the overall pooled estimates of study populations with available
proportions of at least the Brighton level 1 and a suspected ZIKV infection, 57% of cases had
Table 2. (Continued)
First author Journal, year City, country Period Clinical description ZIKV diagnosis
Reyna-Villasmil[45] Med Clin
2016
Zulia,
Venezuela
2016 28 y/o pregnant woman (normal birth). Tetraparesis,
bulbar palsy, areflexia, progressing to respiratory
dysfunction. Preceding (10d) fever, rash, myalgia,
conjunctivitis. CSF: ACD. EMG: AIDP. Brighton 1.
Treatment: IVIg. ICU and MV. Discharge at 21d
(recovered).
Serology for ZIKV+ (type tests
NR)
Siu[46] Neurology
2016
Tonga,
Polynesia
2016 47 y/o man. Returning from Tonga to New Zealand.
Paresthesias, progressive tetraparesis, areflexia, sensory
and respiratory signs. Preceding (6d) edematous leg with
pustular lesions. CSF: ACD. EMG: AIDP. Brighton 1.
Treatment: IVIg and PE. ICU and MV. Discharge at 33d
(bedbound).
PCR: ZIKV/DENV/CHIKV-
(CSF)ZIKV+/DENV/CHIKV-
(S), DENV NS1-
IgM: ZIKV/DENV+(S)
Zambrano[47] Am J Trop Med
Hyg
2016
Guayaquil,
Ecuador
Mar 2016 57 y/o woman. Paresthesia, facial palsy, tetraparesis,
areflexia. Preceding (5d) headache, fever, lumbar back
pain. CSF: ACD.
Treatment: PE. ICU. Discharge at 10d.
PCR: ZIKV/CHIKV+/DENV-
(S,CSF,U)
NR = Not Reported | y/o = year-old | USA = United States of America | LL = lower limbs | UL = upper limbs | ICU = Intensive Care Unit | MV = mechanical ventilation
| CSF = cerebrospinal fluid | ACD = albuminocytological dissociation | EMG = electromyography/nerve conduction studies | IVIg = intravenous immunoglobulin |
PE = plasma exchange | Brighton = Brighton Collaboration Criteria level | MFS = Miller Fisher Syndrome | ZIKV = Zika virus | CHIKV = chikungunya virus |
DENV = dengue virus | PCR = polymerase chain reaction | VNT = virus neutralization test | DENV NS1 = NS1 antigen of DENV | S = serum | Sa = saliva |
CSF = cerebrospinal fluid | U = urine.
aNot published as a case report but only one case fulfilling our criteria for suspected/probable/confirmed ZIKV in larger cohort of 418 cases.
bReturning travelers with suspected, probable or confirmed ZIKV infection reported to the GeoSentinel Surveillence Network. 93 cases reported, 2 GBS cases, one is
already described in the Kassavetis’ paper, the other is described here.
https://doi.org/10.1371/journal.pntd.0008264.t002
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Brighton level 1 and 44% had a suspected ZIKV infection (Fig 2, S2 Fig). We re-calculated
these pooled frequencies after excluding two studies that only included cases with Brighton
levels 1–2,[23, 26] finding 51% (95%CI: 28–74; I2 89.2%) with Brighton 1 (105/290), and re-
calculated pooled frequencies after excluding eight studies that only included cases with proba-
ble/confirmed ZIKV,[16, 17, 20–23, 28, 31] finding 65% (95%CI: 47–80; I2 93.2%) with a sus-
pected ZIKV infection (319/522).
Clinical characteristics. All but one study reported the presence of clinical symptoms of
infection.[19] Two or more symptoms were present in 91% of cases (378/444; 95%CI 84–96, I2
61.2%). The most common symptoms were rash, fever and arthralgia, with similar pooled fre-
quencies between overall estimates and the probable/confirmed subgroup (Table 4). The
median time between the start of infectious symptoms and neurologic symptoms ranged from
-1 to 12 days in the 16 studies reporting on this (Fig 3). For arbovirus symptoms the heteroge-
neity ranged from considerable (I2 = 75–100%), in the overall analysis, to substantial (I2 = 50–
90%), in the probable/confirmed subgroup.
Among neurologic findings, paresis was reported in all studies, and almost all studies
reported on sensory symptoms, tendon reflexes, and facial palsy, while other symptoms were
reported less frequently. The most frequent neurological findings were limb paresis, sensory
symptoms, and hypo/areflexia. Other frequent symptoms were facial palsy in about half, and bul-
bar palsy and respiratory dysfunction in about a quarter of cases. Frequencies of tetraparesis, sen-
sory deficits, bulbar palsy and ataxia were higher in the probable/confirmed cases compared to
overall proportions (Table 4). Separate data on tetraparesis vs paraparesis were reported in ten
studies.[4, 16–18, 20, 21, 23, 25, 27, 31] Paraparesis was present in 69 of 251 reported cases (24%
95%CI 18–31). This included reports of cases with only lower limb weakness at nadir (30/251),
cases with only lower limb weakness at an unclear time point in the disease (33/251), and cases
that were reported as having a paraparetic variant of GBS (6/251). Heterogeneity in the analysis of
all cases combined was substantial (I2 = 50–90%) for dysarthria, dysphagia, bulbar palsy, sensory
deficits, areflexia/hyporeflexia, ataxia, respiratory dysfunction, and dysautonomia. In the proba-
ble/confirmed subgroup analysis this was substantial only for dysphagia and ataxia.
Diagnostic investigations. PCR, principally in serum, was the most frequently performed
test for ZIKV diagnosis, although anti-ZIKV IgM was positive twice more often (Table 5). In
the CSF, ZIKV PCR was positive in only 10 of 244 tested cases. Presence of neutralizing anti-
bodies against ZIKV in the serum was tested in eight studies.[4, 15, 17, 23, 24, 26, 27, 31] To
differentiate ZIKV from DENV, IgM antibodies against DENV were tested in 18 studies (426
cases), and were positive in 70 patients.[4, 14–18, 21, 23–33] Of these patients, 54 were also
positive for ZIKV PCR, IgM and/or ZIKV neutralizing antibodies, and in 16 cases no separate
information on ZIKV test results was available. Infection with CHIKV was investigated in
nine studies and 187 cases, of which 16 were PCR or IgM positive.[14, 17, 19–21, 25, 28, 30]
Only five studies tested all ZIKV suspected cases for other infections that have been associ-
ated with GBS (C.jejuni, CMV, EBV, Hepatitis E virus, Mycoplasma pneumoniae).[4, 17, 23,
26, 31] And all tested cases (80/587; 14%) were negative for recent infection. None of the stud-
ies tested for all of these pathogens. Heterogeneity was considerable for all ZIKV laboratory
tests (I2 = 75–100%).
CSF was examined in most studies, and information on protein level and cell count was
provided by about half of these. Increased protein level and albuminocytological dissociation
were present in the vast majority of cases and results were similar between all studies com-
bined and the probable/confirmed subgroup. Eleven studies reported the CSF cell count,
which did not exceed 55 cells/mm3, and medians were below 5 cells/mm3 (Fig 4).[4, 16–18, 20,
21, 26, 27, 29, 31, 32] Heterogeneity was limited for increased protein level and albuminocyto-
logical dissociation in all studies combined and the probable/confirmed subgroup.
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Fig 2. Overall pooled proportions (forest plots) of Brighton classification of GBS cases during ZIKV epidemics.
https://doi.org/10.1371/journal.pntd.0008264.g002
Table 4. Demographics and clinical characteristics of GBS cases associated with ZIKV reported in 21 case series.
All cases (N 587) Probable/confirmed ZIKV infection (N
165)
Demographics
Adults % (n/N) 98% (550/563) 100% (165/165)
Female % (n/N) 38% (216/570) 41% (67/165)
Symptoms
Infectious symptoms n/N Pooled proportion (95%CI; I2) n/N Pooled Proportion (95%CI; I2)
Arboviral symptoms
Rash 253/544 56% (43–69; 83%) 86/149 61% (37–82; 78%)
Fever 228/539 45% (33–57; 77%) 66/149 42% (21–64; 75%)
Arthralgia 150/539 35% (21–49; 86%) 50/149 31% (15–50; 64%)
Myalgia 126/550 25% (12–41; 89%) 40/149 29% (7–55; 83%)
Headache 106/550 22% (8–38; 91%) 32/149 25% (5–50; 83%)
Conjunctivitis 98/539 17% (8–28; 80%) 30/149 15% (7–24; 14%)
Ocular pain 24/550 1% (0–6; 74%) 3/149 0% (0–3; 41%)
Gastrointestinala 59/550 8% (3–14; 66%) 15/149 6% (0–21; 67%)
Rhinorrhea 12/550 0% (0–1; 0%) 1/149 0% (0–0; 0%)
Cough or chest pain 28/550 2% (0–7; 71%) 9/149 2% (0–13; 61%)
Neurologic symptoms n/N Pooled proportion (95%CI; I2) n/N Pooled proportion (95%CI; I2)
Sensory symptoms 333/421 82% (76–88; 30%) 97/119 86% (73–96; 34%)
Dysphagia 133/351 30% (17–45; 90%) 49/112 34% (7–67; 85%)
Dysarthria 64/281 11% (1–25; 78%) 3/13 17% (0–60; 48%)
Diplopia 11/234 0% (0–4; 33%) 1/13 2% (0–25; 0%)
Neurologic signs n/N Pooled proportion (95%CI; I2) n/N Pooled proportion (95%CI; I2)
Facial palsy 246/486 51% (44–58; 36%) 75/139 56% (42–71; 38%)
Bulbar palsy 60/182 25% (10–42; 70%) 4/11 32% (0–76; 33%)
Ocular palsy 22/232 5% (0–12; 46%) 0/11 0% (0–19; 0%)
Any limb paresis 544/582 97% (93–99; 49%) 153/165 98% (93–100; 17%)
Tetraparesis 153/251 64% (51–77; 53%) 79/110 74% (61–87; 25%)
Paraparesis 69/251 24% (18–31; 0%) 21/110 15% (7–24; 0%)
Sensory deficits 155/317 49% (29–68; 86%) 59/104 59% (39–78; 48%)
Areflexia or hyporeflexia 400/435 96% (88–100; 79%) 131/142 97% (86–100, 56%)
Ataxia 76/317 17% (4–35; 87%) 34/91 29% (4–61; 74%)
Respiratory dysfunctionb 124/369 23% (13–35; 77%) 37/104 24% (10–41; 38%)
Dysautonomia 73/359 13% (5–24; 71%) 21/102 16% (8–26; 0%)
GBS classification n/N Pooled proportion (95%CI; I2) n/N Pooled proportion (95%CI; I2)
Brighton criteria
Level 1–3 396/407 100% (97–100; 56%) 128/135 99% (93–100; 49%)
Level 4 13/407 0% (3–100; 62%) 7/135 1% (0–11; 54%)
Miller Fisher Syndrome 11/419 0% (0–2; 53%) 1/137 0% (0–0; 0%)
Other variants 3/419 0% (0–0; 0%) 0/137 0% (0–0; 0%)
Brighton level = Brighton Collaboration Criteria[10] levels.
aNausea, vomiting or diarrhea.
bReported as ‘trouble breathing’, ‘difficulty breathing’ or ‘respiratory dysfunction’
https://doi.org/10.1371/journal.pntd.0008264.t004
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Electrophysiological studies were done in about half of reported cases. In five studies no
information on electrophysiological examination was reported.[16, 19, 28–30] Criteria used to
classify cases into the different electrophysiological subtypes were reported in only five studies,
[18, 23, 26, 31, 32] and included criteria by Hadden et al, Ho et al, and Rajabally et al.[50–52].
The most frequent electrophysiological subtype was AIDP in 62% (95%CI 38–83), followed by
AMAN in 16% (95%CI 0–41), with both similar pooled proportions in the probable/confirmed
ZIKV subgroup. In most studies, the majority of cases had an AIDP subtype, except for the
study from French-Polynesia[4] where all cases were classified as AMAN, three studies with
similar percentages of AMAN and AIDP,[20, 22, 27] a study from Singapore[15] with similar
frequencies of AIDP and a normal EMG (in patients with MFS), and a Brazilian case series[21]
reporting only a normal EMG and AMAN or AMSAN subtypes.
Treatment and disease progression. All but three studies[15, 20, 30] provided informa-
tion on treatment, and in most studies almost all cases were treated with IVIg, except for three
large studies, from Colombia[24, 32] and Brazil[19], where only 55–70% of patients were
treated with immunomodulating therapy. Three studies provided no information on ICU
admission,[23, 29, 30] which was necessary in about 50% of all reported cases, and even more
Fig 3. Per study medians and ranges of days of time between onset of infectious and neurologic symptoms, and the progressive and plateau phase of GBS cases. ()
= inter quartile range, [] = range.
https://doi.org/10.1371/journal.pntd.0008264.g003
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Table 5. Ancillary investigations, treatment and disease progression of GBS cases associated with ZIKV reported
in 21 case series.
Ancillary investigations All cases (N 587) Cases with probable/confirmed ZIKV
infection (N 165)
n/N Pooled proportion (CI; I2) n/N Pooled proportion (CI; I2)
Zika virus certainty level
Confirmed 118/570 24% (11–40; 92%) 88/165 63% (32–90; 90%)
Probable 128/570 14% (3–30; 93%) 75/165 36% (9–67; 90%)
Suspected 324/570 44% (28–62; 92%) ----- -----
Arboviral tests
ZIKV infectiona
PCR (any sample) 118/470 30% (15–47; 90%) 88/153 71% (40–95; 88%)
PCR Serum 43/409 10% (1–24; 87%) 42/134 32% (5–66; 89%)
PCR CSF 10/244 3% (0–16; 74%) 6/78 11% (0–38; 80%)
PCR Urine 48/253 28% (7–54; 90%) 31/69 63% (21–97; 81%)
IgM (any sample) 254/375 68% (49–85; 90%) 126/137 97% (87–100; 52%)
IgM Serum 228/374 67% (45–85; 91%) 124/137 94% (81–100; 66%)
IgM CSF 36/111 60% (7–100; 95%) 33/50 77% (23–100; 91%)
PRNT ZIKV 121/154 86% (62–100; 86%) 23/23 100% (94–100; 0%)
PRNT ZIKV>DENV 20/105 16% (7–26; 14%) 11/18 67% (20–100; 52%)
DENV infection (PCR) 3/235 0% (0–1; 0%) 2/75 0% (0–10; 35%)
CHIKV infection (PCR or IgM) 16/187 1% (0–8; 56%) 4/88 0% (0–10; 29%)
DENV and CHIKV co-infection 6/165 1% (0–14; 71%) 2/84 0% (0–8; 42%)
CSF analysis 425/537 92% (79–100; 92%) 122/139 99% (87–100; 65%)
Increased protein levelb 253/289 94% (89–98; 19%) 64/70 97% (89–100; 0%)
ACD 276/335 89% (80–96; 64%) 91/99 98% (92–100; 0%)
Electrophysiological exam 245/477 68% (49–85; 93%) 86/145 77% (46–98; 88%)
AIDP 143/244 62% (38–83; 89%) 62/86 68% (44–88; 59%)
AMAN 58/244 16% (0–41; 92%) 11/85 13% (1–33; 56%)
AMSAN 13/244 1% (0–6; 51%) 9/85 3% (0–11; 8%)
Equivocal 9/240 0% (0–2; 0%) 0/86 0% (0–0; 0%)
Unexcitable 4/240 0% (0–0; 0%) 1/86 0% (0–1; 0%)
Normal 11/245 0% (0–4; 26%) 2/86 0% (0–1; 0%)
Immunomodulatory treatment 458/555 92% (81–99; 88%) 153/160 100% (97–100; 8%)
IVIg 441/555 89% (77–97; 90%) 152/160 99% (94–100; 27%)
Plasma exchange 6/555 0% (0–0; 0%) 1/160 0% (0–0; 0%)
IVIg and plasma exchange 11/555 0% (0–1; 25%) 0/160 0% (0–0; 0%)
Disease progression
Admission to ICU 287/544 49% (35–62; 86%) 82/146 57% (29–84; 86%)
Mechanical ventilation 118/567 21% (15–28; 44%) 35/140 19% (7–34; 57%)
Died 23/485 1% (0–3; 0%) 4/133 0% (0–2; 0%)
Abbreviations: ZIKV = Zika virus | CHIKV = Chikungunya virus | DENV = Dengue virus | PCR = polymerase chain
reaction | CSF = cerebrospinal fluid | ACD = albuminocytological dissociation | AIDP = acute inflammatory
demyelinating polyradiculoneuropathy | AMAN = acute motor axonal neuropathy | AMSAN = acute motor sensory
axonal neuropathy | IVIg = intravenous immunoglobulin | ICU = Intensive Care Unit
aProportions calculated per case, not per biological sample.
bDefinition of increased protein level in CSF differed per study (>45 mg/dL, >51mg/dL or no cut-off reported).
https://doi.org/10.1371/journal.pntd.0008264.t005
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frequent in the probable/confirmed subgroup (57%, 95%CI 29–84). Mechanical ventilation
(MV) was necessary in about 20% of all cases and of the probable/confirmed subgroup. Death
was infrequent in all cases combined and the probable/confirmed subgroup. Heterogeneity
was substantial for immunomodulatory treatment and ICU admission, and moderate for MV
(Table 5). We recalculated the pooled proportions of ICU, MV and death after excluding three
studies that only selected cases admitted to the ICU,[17, 22, 28] and found that ICU admis-
sions (261/518) were lower although still frequent (40%, 95%CI: 28–52), frequency of MV
(111/441) was unchanged (22%, 95%CI: 16–28), and frequency of death (22/475) was similar
(2%, 95%CI 0–4%), with comparable frequencies in the probable/confirmed subgroup
analysis.
Eight studies informed about the time between onset and nadir of neurologic deficits (pro-
gressive phase), and only three studies reported the duration of the plateau phase (Fig 3). Only
one large study from French-Polynesia informed about the functional evaluation of mobility
of patients at nadir, showing incapacity to walk in 27/42 and difficulty to walk in 3/42.[4] The
mobility of patients at 6 months after onset of disease was described in a study from Brazil[27]
(33/50 walking without aid, 17/50 incapacity to walk) and a study from Puerto Rico[25] (48/79
able to walk 10 meters without aid, 39/79 any difficulty walking, and 12/79 incapacity to walk).
Discussion
Our systematic review and meta-analysis show that published studies on ZIKV-related GBS
typically report a classic sensorimotor type of GBS often with a facial palsy and a demyelinating
electrophysiological subtype. The disease course is frequently severe with high rates of respira-
tory dysfunction and ICU admission. The time between onset of infectious and neurologic
symptoms and negative PCR in most patients suggests a post-infectious rather than a direct
infectious disease mechanism. These results should however be interpreted with caution as the
studies included in this systematic review are variable in study design and setting, selection cri-
teria, diagnostic ascertainment, and reporting of variables, which are potential sources of bias.
Fig 4. Overview of cell count in the CSF in reported studies. Cell count in medians, () = inter quartile range, [] = range.
https://doi.org/10.1371/journal.pntd.0008264.g004
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The combination of sensorimotor signs with facial palsy and respiratory insufficiency and a
demyelinating electrophysiological subtype has previously been described in GBS patients
with other preceding virus infections, such as CMV, indicating that such a clinical and
electrophysiological profile may be related to preceding virus infections in general, in contrast
to a bacterial infection with C.jejuni, that is associated with a pure motor axonal type of GBS.
[7, 8, 53, 54] Additionally, although GBS is generally more common in men than in women,
we found equal distributions of male and female frequencies in larger studies, similar to previ-
ous reports on GBS after other virus infections, suggesting that females may be more prone to
virus-related GBS.[7, 53] This finding could however also be due to a higher incidence of
ZIKV disease in females compared to males as has been shown in some studies.[55, 56]
Another interesting finding was the high frequency of paraparesis (24%) compared to previous
literature on GBS (1–11%), indicating that this may be a GBS variant related to ZIKV, although
a lower percentage of paraparesis in the subgroup of patients with probable/confirmed ZIKV
makes this feature less specific.[5, 57, 58] Furthermore, in some studies it is not clear if the
paraparesis evolved to tetraparesis at a later time point, and whether myelitis, which has been
linked to ZIKV in other studies, was excluded.[5, 57–59]
Some included studies diverged from the generally reported phenotype. Most importantly,
the study from French Polynesia[4], in which all 42 patients had an AMAN electrophysiologi-
cal subtype, 17 (40%) had a paraparesis and only 26 (62%) had hypo- or areflexia; and the
study from Singapore[15], in which 4 out of 12 patients (33%) had MFS and one (8%) had
MFS-GBS overlap syndrome. The high percentage of MFS in Singapore is in line with other
publications that show high prevalence of MFS in Asian countries, but whether an AMAN
subtype is typical for the Pacific region has not been studied.[5] As most of the other studies
described cases from Latin America and the Caribbean, these discrepancies may be due to
regional differences in host and/or environmental factors, including differences in the ZIKV
strains.[5, 60] However, some dissimilarities could also be due to differences in diagnostic and
electrophysiological accuracy between studies. For instance, the interpretation of electrophysi-
ological data in the study from French Polynesia[4] has previously been questioned, as the pro-
longed distal motor latencies, found at first examination and persisting after 4 months, would
be more consistent with the AIDP subtype.[61]
The median time between the onset of infectious symptoms and the start of neurologic
symptoms varied between 5 and 12 days, which is similar to other infections preceding GBS.
[7, 62, 63] Considering that the incubation period of ZIKV infection is estimated at 1–2 weeks,
the latency between ZIKV infection and GBS was more than a week for most cases, suggesting
a post-infectious immunopathogenesis, rather than direct neuronal damage or a para-infec-
tious mechanism, as has been suggested in previous publications.[64, 65] A low frequency of
ZIKV PCR positivity in blood and CSF, and a low cell count in the CSF in the majority of
cases, further argues against a direct infection. These findings are in line with an in vivo study
that showed resistance of peripheral nerve cells to infection by ZIKV.[66]
Remarkably, half of all cases combined and more than a half of probable/confirmed cases
were admitted to the ICU. This proportion is higher than expected based on other literature
(15–30%)[67, 68], and remained higher (40%) after we excluded papers that only included
patients admitted to the ICU. These data may indicate that GBS following ZIKV infection is
often severe enough to necessitate ICU admission. However, the percentage of mechanically
ventilated patients (20%) is similar to most other publications.[5, 58, 69, 70] It is not clear what
causes this discrepancy. A possible explanation is that presence of autonomic symptoms, rapid
progression, severe weakness, or respiratory problems that did not evolve into respiratory
insufficiency, were reasons to admit to the ICU, especially during the ZIKV epidemic when an
increased vigilance for GBS may have lowered the threshold for intensive care monitoring.
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Furthermore, many studies were done in specialized centres that may receive more severely
affected patients referred from other centres, or may more easily admit patients to the ICU for
monitoring compared to non-specialized centres.
The large variability of study designs and settings, selection criteria, diagnostic ascertain-
ment and citation of variables were important sources of bias within studies and heterogeneity
across studies, which is a critical limitation of our meta-analysis. Most importantly, diagnostic
ascertainment of GBS and ZIKV differed, and electrophysiological criteria were not reported
in most studies. Diagnostic certainty of ZIKV infection was limited in most studies, and other
preceding infections in GBS were often not excluded. Furthermore, the type of hospital may
have biased the inclusion of severe cases, causing heterogeneity in both clinical signs and dis-
ease progression. We calculated the I2 to quantify this heterogeneity between studies, and have
performed a sensitivity analysis to estimate the pooled frequencies among a subgroup of cases
with only probable/confirmed ZIKV to analyse the clinical picture of GBS among cases with a
higher ascertainment of ZIK infection.
The I2 was considerable for most infectious symptoms, which is likely due to recall and
reporting bias, and as we assumed infectious symptoms were absent, rather than missing, if
not reported, we may have increased this heterogeneity. Heterogeneity in neurologic symp-
toms and signs was considerable for some variables, which may be due to differences in study
design and methodology and geographical location. Heterogeneity of arboviral test results was
also considerable, which may be due to differences between timing of sample collection and
variation in incubation and viremia periods. In general, the variables with considerable hetero-
geneity are difficult to interpret and preclude any firm conclusions to be drawn from these
data. However, the I2 in the probable/confirmed ZIKV subgroup was generally lower than in
all cases combined, indicating that the heterogeneity was partly caused by differences in the
diagnostic certainty of ZIKV infection, providing more evidence for a specific clinical and
electrophysiological phenotype of ZIKV-related GBS.
Conclusion
Published studies on ZIKV-related GBS generally report a sensorimotor demyelinating GBS
with a frequent facial palsy and a severe disease course that often necessitates ICU admittance.
The paraparetic variant of GBS is also common, which should caution clinicians to exclude
myelitis in ZIKV-related cases. The time between onset of infectious and neurologic symptoms
and absence of viral genome detected by PCR in most cases suggest a post-infectious, rather
than a direct infectious or para-infectious mechanism.
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